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Potassium represents a key ion of the human body; 98% of the body's potassium pool is present in the intracellular compartment, leading to a steep potassium concentration gradient across cellular membranes. This indicates why potassium is particularly important to maintain the cellular membrane potential. It is therefore not surprising that changes in the potassium concentration in the extracellular and subsequently also in the intracellular compartment have a striking impact on the myocardial conduction system leading to cardiac arrhythmias. Hence, the human body aims to maintain the serum potassium concentration within narrow limits (i.e. 3.5-5.0 mmol/L) by cellular potassium shifts, renal excretion, and intestinal secretion. Increased or reduced dietary potassium intake can be counterbalanced over a wide range. If dietary potassium intake decreased to zero, it would take 2-3 weeks until changes of the serum potassium concentration would occur. 1 Therefore, changes in the serum potassium levels are mainly caused by external influences (e.g. medications) or abnormalities of the aforementioned potassium-regulating elements [e.g. chronic kidney disease (CKD)].
In their manuscript published in this issue of the journal, Kovesdy and colleagues provide one of the largest reports on the association between serum potassium and mortality in 1 217 986 subjects (27 cohorts) from the general population, patients at high cardiovascular risk, and patients with CKD. 2 As expected, the authors identified CKD as an important risk factor for hyperkalaemia. Interestingly, in patients with an estimated glomerular filtration rate (eGFR) <30 mL/ min, the risk of hyperkalaemia and hypokalaemia was likewise increased. Moreover, it is not surprising that the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) was associated with an increased risk for hyperkalaemia and diuretics, with an increased risk for hypokalaemia. Based on the large sample size, the authors could intriguingly document that even minor deviations of the serum potassium concentration from the normal range were already associated with increased risk for all-cause mortality and somewhat weaker also for cardiovascular mortality. This association was present within all strata of eGFR and not affected by the use of diuretics or RAAS inhibitors in subgroup analyses. Moreover, the authors found an association between low and high serum potassium levels and the risk of end-stage renal disease. This finding might be related to the presence of residual confounders such as the higher prevalence of structural heart disease, atherosclerotic vascular lesions, and CKD itself. Although the present findings are strongly corroborated by the large number of participants, changes in medication during follow-up and missing information on supplementation with potassium might introduce a certain bias. Nevertheless, the present study is of great importance for all clinicians, be it cardiologists, nephrologists, or general practitioners being responsible for patients treated with RAAS inhibitors or diuretics, or patients with CKD and other conditions affecting serum potassium levels. It is suggested that hypokalaemia is present in 3% of all patients on hospital admission and even in 20% of all hospitalized patients. 1 In particular, in patients with chronic heart failure (CHF) and CKD treated with either loop diuretics or thiazide diuretics, the prevalence of hypokalaemia might be substantially higher. 3 While many efforts are made to prevent hyperkalaemia, hypokalaemia represents a highly prevalent disturbance of electrolyte metabolism, but less attention is paid to it in clinical practice and research. However, Kovesdy et al. could document that already slightly reduced serum potassium concentrations were associated with increased mortality. Therefore, in patients on diuretic therapy, serum potassium concentrations should be regularly monitored and, in the case of hypokalaemia, potassium supplementation should be initiated and/or thiazide and loop diuretics should be combined with potassium-sparing diuretics. In contrast to hypokalaemia, which usually can be easily corrected by potassium supplementation, the correction of hyperkalaemia and maintenance of normal serum potassium levels is more challenging and an important issue in patients with CHF and CKD, particularly in those on higher dose chronic RAAS inhibition therapy. During the last decades, angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARB) have emerged as important antiproteinuric treatment strategies in patients with, for example, diabetic nephropathy, but are also an important first step in the supportive therapy of patients with glomerulonephritis. While hyperkalaemia is only present in 2% of patients treated with RAAS inhibitors due to hypertension with apparently normal kidney function, 4 the incidence of hyperkalaemia in patients with CKD is substantially higher. In the IDNT (Irbesartan Diabetic Nephropathy) trial of patients with type 2 diabetes and diabetic nephropathy (i.e. serum creatinine 1.0-3.0 mg/dL in women and 1.2-3.0 mg/dL in men), the incidence of hyperkalaemia as defined by a serum potassium > _6.0 mmol/L was 18.6%. 5 In studies with a similar design, the incidence of hyperkalaemia was in a comparable range. 4 Moreover, enhancing the antiproteinuric effects by dual therapy with an ACEi and ARB (ONTARGET study) had no benefit, while adverse events and, here in particular, hyperkalaemia was increased. 6 Similarly, patients with CHF are also at high risk for hyperkalaemia. 7 According to the recent ESC guidelines, 8 treatment with
an ACEi or ARB represents a cornerstone in the treatment algorithm of symptomatic patients with CHF with reduced ejection fraction (HFrEF). In a second step, in patients with left ventricular ejection fraction (LVEF) < _35%, the additional use of mineralocorticoid antagonists (MRAs) has shown clear benefits, reducing mortality and hospitalization. 8 Notably, the combination of both substances substantially augments the risk of hyperkalaemia. Therefore, regular monitoring of serum potassium levels in these patients is mandatory. Additionally, the prevalence of CKD in patients with CHF is very high, which considerably increases the risk of hyperkalaemia in these patients. 9 This leads to an inevitable rate of discontinuation of the therapy and lower doses prescribed, 10 although exactly those patients would benefit from high-intensity therapy.
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Until now, no efficient potassium-lowering agents were available for long-term use. Sodium polystyrene sulphonate (SPS), which was mainly used in patients with CKD and hyperkalaemia, was approved by the Food and Drug Administration (FDA) in 1958. 4 At that time, no randomized controlled trials were necessary to prove the efficiency of these agents. In practice, SPS treatment is only suitable for short-term treatment since its use is associated with hypernatraemia, volume overload, and gastrointestinal complications. 2 nificantly reduced serum potassium concentrations in outpatients with CHF, CKD, and diabetes with a pattern of adverse events similar to that of patiromer, but FDA approval for ZS-9 is still pending. Nevertheless, both potassium-lowering agents could provide a powerful treatment strategy to prevent discontinuation or dose reductions of RAAS inhibitor therapy in patients with CHF and/or CKD. However, their long-term effects, for example on the gastrointestinal tract, have to be evaluated. In summary, the study of Kovesdy and colleagues clearly documents the association of hyperkalaemia and hypokalaemia with mortality. 2 In particular, in patients with CHF and CKD at high risk for abnormalities of serum potassium, accurate and frequent monitoring is mandatory. Abnormal potassium should lead to either potassium supplementation or treatment with potassium-lowering agents for hypokalaemia and hyperkalaemia, respectively. Novel potassium-lowering therapeutics may provide a useful option in patients with manifest hyperkalaemia or at high risk for hyperkalaemia. Future studies have to explore the effect of such therapies on outcomes in patients on RAAS inhibition requiring continuous potassium-lowering treatment.
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